Blog Read the latest perspectives from our team of subject matter experts and others CEO Insights: Solving Healthcare’s Provider Data Challenge Through H1’s Acquisition of VedaToday, I’m proud to announce that H1 is acquiring Veda. This follows our acquisition of Ribbon Health in December 2024. By bringing in Veda’s suite of products, data, team, and… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology KOL EngagementNavigating HCP Digital Engagement: Best PracticesAs medical education evolves, the need for effective digital engagement strategies is also growing. In order to ensure that healthcare professionals (HCPs) have access to the most up-to-date information… Continue reading → Read the articleno Artificial IntelligenceThe Power of Data: Three Ways to Rethink AI HallucinationsIn this new content series, H1’s Senior Director of Strategic Commercial Engagement, Robert Consalvo, writes about leveraging generative AI for business, digital health, life sciences, biotech and pharma and the… Continue reading → Read the articleno Artificial IntelligenceBalancing Creativity and Accuracy in Artificial IntelligenceIn the realm of AI, balancing creativity and accuracy is a critical consideration, especially when developing AI systems for business applications. While creativity adds novelty and innovation to outputs,… Continue reading → Read the articleno CommercializationDrug DevelopmentWhat Payer Trends Can Tell Us About Medication AdherenceOne thing the healthcare ecosystem lacks in the United States is a system of shareable, actionable healthcare data. So where is one possible place pharma can look for insights… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationImproving Oncology Clinical Trials for Accelerated ApprovalIn March of 2023, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design specific… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Drug Approvals and Development Hinge on DiversityThe success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within… Continue reading → Read the articleno«‹2345678›»
